Benjamin F. Edwards & Company’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $2.76M | Buy |
5,892
+932
| +19% | +$405K | 0.05% | 323 |
|
|
2024
Q1 | $2.07M | Buy |
4,960
+1,288
| +35% | +$544K | 0.04% | 356 |
|
|
2023
Q4 | $1.49M | Buy |
3,672
+859
| +31% | +$317K | 0.03% | 402 |
|
|
2023
Q3 | $978K | Buy |
2,813
+126
| +5% | +$44.1K | 0.04% | 381 |
|
|
2023
Q2 | $946K | Buy |
2,687
+99
| +4% | +$33.4K | 0.04% | 385 |
|
|
2023
Q1 | $815K | Sell |
2,588
-96
| -4% | -$28.8K | 0.03% | 379 |
|
|
2022
Q4 | $775K | Hold |
2,684
| – | – | 0.03% | 372 |
|
|
2022
Q3 | $777K | Sell |
2,684
-2
| -0.1% | -$575 | 0.04% | 358 |
|
|
2022
Q2 | $757K | Sell |
2,686
-598
| -18% | -$160K | 0.04% | 379 |
|
|
2022
Q1 | $857K | Hold |
3,284
| – | – | 0.04% | 370 |
|
|
2021
Q4 | $721K | Buy |
3,284
+600
| +22% | +$117K | 0.03% | 406 |
|
|
2021
Q3 | $487K | Hold |
2,684
| – | – | 0.02% | 452 |
|
|
2021
Q2 | $541K | Sell |
2,684
-802
| -23% | -$168K | 0.03% | 432 |
|
|
2021
Q1 | $749K | Buy |
3,486
+86
| +3% | +$18.9K | 0.04% | 377 |
|
|
2020
Q4 | $804K | Buy |
3,400
+119
| +4% | +$27.3K | 0.05% | 342 |
|
|
2020
Q3 | $893K | Sell |
3,281
-855
| -21% | -$236K | 0.06% | 293 |
|
|
2020
Q2 | $1.2M | Buy |
4,136
+1,157
| +39% | +$314K | 0.09% | 236 |
|
|
2020
Q1 | $709K | Buy |
2,979
+183
| +7% | +$42K | 0.06% | 282 |
|
|
2019
Q4 | $612K | Hold |
2,796
| – | – | 0.04% | 340 |
|
|
2019
Q3 | $474K | Buy |
2,796
+2,582
| +1,207% | +$457K | 0.04% | 376 |
|
|
2019
Q2 | $39K | Buy |
214
+6
| +3% | +$1.05K | ﹤0.01% | 976 |
|
|
2019
Q1 | $38K | Hold |
208
| – | – | ﹤0.01% | 949 |
|
|
2018
Q4 | $34K | Buy |
208
+42
| +25% | +$7.28K | ﹤0.01% | 944 |
|
|
2018
Q3 | $32K | Buy |
166
+56
| +51% | +$9.97K | ﹤0.01% | 984 |
|
|
2018
Q2 | $19K | Buy |
110
+10
| +10% | +$1.55K | ﹤0.01% | 1115 |
|
|
2018
Q1 | $16K | Hold |
100
| – | – | ﹤0.01% | 1143 |
|
|
2017
Q4 | $15K | Hold |
100
| – | – | ﹤0.01% | 1103 |
|
|
2017
Q3 | $15K | Sell |
100
-14
| -12% | -$2.11K | ﹤0.01% | 1052 |
|
|
2017
Q2 | $15K | Hold |
114
| – | – | ﹤0.01% | 970 |
|
|
2017
Q1 | $12K | Hold |
114
| – | – | ﹤0.01% | 977 |
|
|
2016
Q4 | $8K | Hold |
114
| – | – | ﹤0.01% | 996 |
|
|
2016
Q3 | $10K | Buy |
114
+14
| +14% | +$1.32K | ﹤0.01% | 854 |
|
|
2016
Q2 | $9K | Hold |
100
| – | – | ﹤0.01% | 831 |
|
|
2016
Q1 | $8K | Hold |
100
| – | – | ﹤0.01% | 856 |
|
|
2015
Q4 | $13K | Hold |
100
| – | – | ﹤0.01% | 791 |
|
|
2015
Q3 | $10K | Sell |
100
-438
| -81% | -$56.3K | ﹤0.01% | 876 |
|
|
2015
Q2 | $66K | Buy |
538
+259
| +93% | +$32.6K | 0.01% | 540 |
|
|
2015
Q1 | $33K | Buy |
279
+179
| +179% | +$21.4K | 0.01% | 654 |
|
|
2014
Q4 | $12K | Hold |
100
| – | – | ﹤0.01% | 767 |
|
|
2014
Q3 | $11K | Hold |
100
| – | – | ﹤0.01% | 753 |
|
|
2014
Q2 | $9K | Hold |
100
| – | – | ﹤0.01% | 754 |
|
|
2014
Q1 | $7K | Hold |
100
| – | – | ﹤0.01% | 742 |
|
|
2013
Q4 | $7K | Sell |
100
-31
| -24% | -$2.16K | ﹤0.01% | 713 |
|
|
2013
Q3 | $10K | Hold |
131
| – | – | ﹤0.01% | 611 |
|
|
2013
Q2 | $10K | Buy |
+131
| New | +$9.65K | ﹤0.01% | 574 |
|
Other funds holding VRTX
Benjamin F. Edwards & Company's VRTX Position: Q2 2024 in Review
Benjamin F. Edwards & Company increased its Vertex Pharmaceuticals (VRTX) stake by 19% in Q2 2024, buying an estimated $405K and bringing the position to 5,892 shares worth $2.76M. The position accounts for 0.05% of the portfolio, ranked #323.
Benjamin F. Edwards & Company first reported a position in VRTX in Q2 2013 and has held it in 45 quarters since. 1,547 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.
- Benjamin F. Edwards & Company held 5,892 shares of Vertex Pharmaceuticals worth $2.76M as of Q2 2024.
- Benjamin F. Edwards & Company bought 932 Vertex Pharmaceuticals shares in Q2 2024, an estimated $405K.
- Vertex Pharmaceuticals made up 0.05% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #323 holding.
- Benjamin F. Edwards & Company first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- 1,547 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.
Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.